Triple Tandem Mimotope Peptide of Epidermal Growth Factor ReceptorDisplaying on the Surface of M13 Phage Induces Anti-Tumor Response in MiceTumor Model

Javanmardi, Masoud; Rasaee, Mohammad Javad; Modjtahedi, Helmout; Asadi-Ghalehni, Majid; Maghami, Mohammad Ghaem

doi:10.15171/ijb.1017

Cited by 4 publications

(7 citation statements)

References 33 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, this mimotope was established using the phage display method 47 . In another study, mimotopes (with low molecular weights) were expressed on the surface of phage particles and were used as a substitute of natural EGFR to induce an ‘active’ immunity responsible for a long term humoral response 48 . In an additional study, a mimotope was extracted from tocilizumab which could induce dual humoral and cellular responses of the immune system 49 .…”

Section: Discussionmentioning

confidence: 99%

“…Mimotopes have short linear amino acid sequences and are ‘easy’ to produce, which makes them suitable substitutes of natural epitopes. Mimotopes can even be synthesised for undetected epitopes, because knowledge of the antigenic amino acid sequence is not required for their production 48 . Different research teams have produced a variety of mimotopes for different disorders and have used distinct approaches.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis

Karami

Sabatier

Behdani

et al. 2020

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

Vascular Endothelial Growth Factor (VEGF) promotes angiogenesis in tumours of various cancers. Monoclonal antibodies and nanobodies are one of the potent agents in the treatment of cancer. Due to their high costs, researchers are considering to design and produce peptides as a substitute approach in recent years. The aim of the current study was designing a mimotope against VEGF and evaluate its effects on cell proliferation and tube formation in the HUVEC cell line. For this, a peptide was designed against VEGF and chemically produced. The effects of synthetic peptide and nanobody on the inhibition of proliferation of HUVEC cells were examined using MTT and tube formation assays. The data indicate that the peptide was able to significantly inhibit both HUVEC cell proliferation and tube formation through inhibition of VEGF, highlighting the potential of peptides as a 'novel' class of candidate drugs to inhibit angiogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis

Karami

Sabatier

Behdani

et al. 2020

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

show abstract

“…pIII and pVIII proteins are the most used for the display of fusion peptides due to their specific location on the phage structure ( Table 1 ) [ 10 , 32 ]. Short peptides (8 or fewer amino acids) can be effectively fused to many copies of the protein pVIII since the display level have been found to be dependent of the length and sequence of the peptide displayed [ 33 ]. Since the valency (protein copies per viral particle) has a direct relationship with the immune response to be generated, the proportion of immunogenic peptides displayed on protein pVIII has been extensively used for vaccine development [ 31 , 34 , 35 ].…”

Section: Phage-based Vaccinesmentioning

confidence: 99%

“…Since the discovery of the capacity of filamentous phages to exert anti-tumor activity in rabbits and mice [ 33 ], the use of phage particles as immunotherapy to treat melanoma tumors has become a very compelling research field. Studies on the administration of M13 and T4 phages to mice tumor models have demonstrated that the mechanism by which anti-tumor phages induce tumor elimination is mediated by the activation of tumor-associated macrophages in a Myeloid differentiation primary response 88 (MyD88)-dependent way [ 56 ].…”

Section: Phage-based Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Bacteriophage-Based Vaccines: A Potent Approach for Antigen Delivery

et al. 2020

View full text Add to dashboard Cite

Vaccines are considered one of the most important bioproducts in medicine. Since the development of the smallpox vaccine in 1796, several types of vaccines for many diseases have been created. However, some vaccines have shown limitations as high cost and low immune responses. In that regard, bacteriophages have been proposed as an attractive alternative for the development of more cost-effective vaccines. Phage-displayed vaccines consists in the expression of antigens on the phage surface. This approach takes advantage of inherent properties of these particles such as their adjuvant capacity, economic production and high stability, among others. To date, three types of phage-based vaccines have been developed: phage-displayed, phage DNA and hybrid phage-DNA vaccines. Typically, phage display technology has been used for the identification of new and protective epitopes, mimotopes and antigens. In this context, phage particles represent a versatile, effective and promising alternative for the development of more effective vaccine delivery systems which should be highly exploited in the future. This review describes current advances in the development of bacteriophage-based vaccines, with special attention to vaccine delivery strategies. Moreover, the immunological aspects of phage-based vaccines, as well as the applications of phage display for vaccine development, are explored. Finally, important challenges and the future of phage-bases vaccines are discussed.

show abstract

A Recombinant RBD-Based Phage Vaccine Report: A Solution to the Prevention of New Diseases?

Salehi

Rasaee

2023

Vaccines

Self Cite

View full text Add to dashboard Cite

The safety, inherent immunogenicity, stability, and low-cost production of bacteriophages make them an ideal platform for vaccine development. Most vaccination strategies against COVID-19 have targeted the spike protein of SARS-CoV-2 to generate neutralizing antibodies. P1, a truncated RBD-derived spike protein, has been shown to induce virus-neutralizing antibodies in preclinical studies. In this study, we first investigated whether recombinant phages displaying P1 on the M13 major protein could immunize mice against COVID-19, and second, whether inoculation with 50 µg of purified P1 in addition to the recombinant phages would stimulate the immune systems of the animals. The results showed that the mice that received recombinant phages were immunized against the phage particles, but did not have anti-P1 IgG. In contrast, compared with the negative control, the group that received a combination of P1 protein and recombinant phage was immunized against the P1 protein. In both groups, CD4+ and CD8+ T cells appeared in the lung tissue. These results suggest that the number of antigens on the phage body plays a crucial role in stimulating the immune system against the bacteriophage, although it is immunogenic enough to function as a phage vaccine.

show abstract

Triple Tandem Mimotope Peptide of Epidermal Growth Factor ReceptorDisplaying on the Surface of M13 Phage Induces Anti-Tumor Response in MiceTumor Model

Cited by 4 publications

References 33 publications

A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis

A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis

Bacteriophage-Based Vaccines: A Potent Approach for Antigen Delivery

A Recombinant RBD-Based Phage Vaccine Report: A Solution to the Prevention of New Diseases?

Contact Info

Product

Resources

About